Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424186 | 0.94 | TDP1 (0.61) | TDP1BRAFHDAC1SIRT6HSPB1 | |
| SCHEMBL10784720 | 0.86 | TDP1 (0.70) | TDP1SIRT6HPGDSMN1; SMN2MAPT | |
| SCHEMBL1028474 | 0.85 | TDP1 (0.60) | TDP1BRAFHDAC1SIRT6HPGD | |
| SCHEMBL10784985 | 0.82 | TDP1 (0.62) | TDP1SIRT6HPGDSMN1; SMN2MAPT | |
| SCHEMBL2724028 | 0.82 | TDP1 (0.62) | TDP1SIRT6HPGDSMN1; SMN2MAPT | |
| SCHEMBL3512673 | 0.82 | TDP1 (0.62) | TDP1SIRT6HSPB1HPGDSMN1; SMN2 | |
| SCHEMBL12846984 | 0.81 | TDP1 (0.47) | TDP1BRAFHDAC1SIRT6HSPB1 | |
| SCHEMBL1027039 | 0.81 | TDP1 (0.61) | TDP1BRAFHDAC1SIRT6HPGD | |
| SCHEMBL10785510 | 0.81 | TDP1 (0.61) | TDP1SIRT6HPGDSMN1; SMN2MAPT | |
| SCHEMBL17530357 | 0.81 | TDP1 (0.76) | TDP1BRAFHDAC1SIRT6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (LV) | 2011-03-24 | — | — | US | disclosed |
| EP-2274280-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | Biolipox AB (SE) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009127822-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | LTC4S, LTB4R2, LTB4R | TDP1 4176/4885BRAF 4179/4885HDAC1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.